<unk>  is approved in the US and in Europe for the second- or third-line treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC). It is the only ALK inhibitor with meaning activity against ALK G1202R mutation in lung cancer.
Lorlatinib
Tucatinib
Neratinib
Fostamatinib
Lapatinib
Ponatinib
Brigatinib
Selpercatinib